Genomcore (Made of Genes) launches €500,000 crowdfunding round – #BHHMembersInitiatives

Genomcore (BHH member Made of Genes), leading company in data solutions for the implementation of precision medicine, has launched an investment round through BHH member Capital Cell, Europe’s first online investment platform specialized in biomedicine. The goal of the campaign is to reach €500,000 of funding to prepare the entry of a new strategic partner that will accompany the internationalization of the company, eventually concluding in the establishment of the company in the USA.

Genomcore thus seeks to extend internationally the leadership achieved in Spain in genomics and multimodal biomedical data analysis, where it has won three large competitive tenders and grants (DIPCAN, Medigenomics and Missions in A.I. Red.es) worth EUR 1.5M in the last 12 months. To this end, the company presented at this round its plans to evolve its current biomedical data management platform into the world’s first low-code platform specialized in precision medicine, enabling the creation of digital health tools by professionals without programming skills and with fullregulatory compliance.

For this round, the company is negotiating the entry of new corporate partners or professional investors but opens the possibility that any individual investor can participate in the growth of the company from €500 through equity crowdfunding, repeating the success of the round closed in 2019 on the same platform. Among the current investors of the company are relevant names such as Carlos Gallardo (Almirall), Albert Armengol (Doctoralia) or Jordi Esteve (Laboratorios Esteve), as well as early-stage funds from Telefónica (Wayra) and Crèdit Andorrà (Scale Lab) and the Barcelona fund FCV Equity. Most of Genomcore‘s current investors are also participating in this round.

Personalized medicine within the reach of all healthcare professionals

Genomcore allows all types of healthcare professionals without specific technical knowledge to import and integrate genomic data, clinical records, or biometric signals, among others. This information can be used afterwards to create diagnostic tools, integrative reports and patients’ portals/apps within the platform without programming knowledge and always ensuring full regulatory compliance.